Skip to Content

STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC

Phase III Clinical Trial

A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer
Trial Number: 06497556
Trial Status: Call Proj Mgr

Participating Locations